Report: medical affairs a 'constant presence' in Ph IV studies

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/Szepy)
(Image: iStock/Szepy)

Related tags: Clinical trial

As Phase IV studies are ‘undergoing a revolution,’ a recent report suggests that medical affairs teams are apt to head post-marketing study strategy.

The study, recently published​ by pharmaceutical business intelligence firm Cutting Edge Information, explained that this is due to their experience with physicians and medical information groups.

(Image: Cutting Edge Information)
(Image: Cutting Edge Information)

According to the report, the medical affairs team is one of the most involved in Phase IV study development. Of the Ph IV teams surveyed as part of the reserach, 75% reported that medical affairs functions remain “a constant presence during post-marketing execution​.”

Additionally, 93% of medical affairs teams are involved in the strategic planning process for Ph IV studies, according to the report – although only 68% participate in the study execution process.

Phase IV studies are undergoing a revolution​,” Natalie DeMasi, Research Team Leader at Cutting Edge Information, told us.

Notably, she explained that Phase IV studies are no longer seen as optional.

The need to collect health economic outcomes is one high priority reason why postmarketing studies are becoming more popular​,” DeMasi said. “Phase IV studies have become crucial for earning product reimbursement and market share​.”

Collecting ‘true real-world data’

The goal of a Ph IV study is to refine the understating of a medication in the real-world. However, through the research, DeMasi said the company was surprised to learn that that there is some debate on whether sponsor companies should provide the product to patients who participate in prospective observational studies. 

By definition, drug manufacturers should not have any influence on study participants throughout observational trials. Trial teams should allow clinicians and patients to make the best treatment decisions​,” she explained.

According to the report, some drug companies feel they must offer their product, as healthcare systems don’t always want to provide or reimburse the drug. However, as DeMasi explained, contributing to the treatment plan in this way could impact study outcomes.

Essentially, providing the treatment option is an intervention — more aligned with a traditional clinical trial​,” she said, “and by providing the product, that action classifies the study as an interventional trial and no longer qualifies as collecting true real-world data​.”

Related topics: Clinical Development, Phase III-IV

Related news

Show more

Related products

show more

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 21-Sep-2020 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Covance Touchless Drug and Device Vigilance Vision

Covance Touchless Drug and Device Vigilance Vision

Covance Patient Safety | 01-Sep-2020 | Data Sheet

Automation tools enable organizations to identify patterns in structured and unstructured data and facilitate automation of the entire product vigilance...

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Related suppliers

Follow us

Products

View more

Webinars